Pharmacokinetic Research Progress of Anti-tumor Drugs Targeting for Pulmonary Administration

被引:3
|
作者
Zhao, Mengfan [1 ]
Jing, Ziwei [1 ]
Zhou, Lin [1 ]
Zhao, Hongyu [2 ]
Du, Qiuzheng [1 ]
Sun, Zhi [1 ]
机构
[1] Zhengzhou Univ, Dept Pharm, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China
[2] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China
基金
中国国家自然科学基金;
关键词
Lung cancer; inhalation preparation; drug carrier; pharmacokinetics; anti-tumor drugs; pulmonary administration; CELL LUNG-CANCER; MICELLIZING SOLID DISPERSION; DELIVERY-SYSTEMS; DRY POWDER; INHALATION TREATMENT; CYCLOSPORINE-A; PHASE-II; NANOPARTICLES; LIPOSOMES; FORMULATION;
D O I
10.2174/1389200221999201111193910
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Cancer is a major problem that threatens human survival and has a high mortality rate. The traditional chemotherapy methods are mainly intravenous injection and oral administration, but have obvious toxic and side effects. Anti-tumor drugs for pulmonary administration can enhance drug targeting, increase local drug concentration, and reduce the damage to systemic organs, especially for the treatment of lung cancer. Methods: The articles on the pharmacokinetics of anti-tumor drugs targeting pulmonary administration were retrieved from the Pub Med database. This article mainly took lung cancer as an example and summarized the pharmacokinetic characteristics of anti-tumor drugs targeting for pulmonary administration contained in nanoparticles, dendrimers, liposomes and micelles. Results: The review shows that the pharmacokinetics process of pulmonary administration is associated with a drug carrier by increasing the deposition and release of drugs in the lung, and retarding the lung clearance rate. Among them, the surface of dendrimers could be readily modified, and polymer micelles have favorable loading efficiency. In the case of inhalation administration, liposomes exhibit more excellent lung retention properties compared to other non-lipid carriers. Therefore, the appropriate drug carrier is instrumental to increase the curative effect of anti-tumor drugs and reduce the toxic effect on surrounding healthy tissues or organs. Conclusion: In the process of pulmonary administration, the carrier-embedded antitumor drugs have the characteristics of targeted and sustained release compared with non-packaging drugs, which provides a theoretical basis for the clinical rational formulation of chemotherapy regimens. llowever, there is currently a lack of comparative research between drug packaging materials, and more importantly, the development of safe and effective anti-tumor drugs targeting for pulmonary administration requires more data.
引用
收藏
页码:1117 / 1126
页数:10
相关论文
共 50 条
  • [1] Research Progress on Anti-tumor Therapy Targeting Cholesterol Metabolism
    Rilan Bai
    Ling Bai
    Wei Li
    Jiu Wei Cui
    JournalofNutritionalOncology, 2017, 2 (04) : 159 - 164
  • [2] Research Progress of Small-Molecule Targeted Anti-Tumor Drugs
    Zhou, Wentao
    INTERNATIONAL CONFERENCE ON FRONTIERS OF BIOLOGICAL SCIENCES AND ENGINEERING (FBSE 2018), 2019, 2058
  • [3] Research Progress on the Synergistic Anti-Tumor Effect of Natural Anti-Tumor Components of Chinese Herbal Medicine Combined with Chemotherapy Drugs
    Zhou, Hongrui
    Zhang, Mengxue
    Cao, Huihui
    Du, Xintong
    Zhang, Xin
    Wang, Jin
    Bi, Xiuli
    PHARMACEUTICALS, 2023, 16 (12)
  • [4] Research progress on anti-tumor mechanisms of scutellarin
    Ge, Hai-Chao
    Zhong, Xiu-Hong
    JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH, 2024, 26 (11) : 1261 - 1275
  • [5] Progress in Research on the Anti-tumor Effect of Artesunate
    何荣荣
    周怀君
    Chinese Journal of Integrative Medicine, 2008, 14 (04) : 312 - 316
  • [6] Research progress on the anti-tumor effect of Naringin
    He, Jing
    Zhang, Hui-Ping
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [7] Progress in Research on the Anti-tumor Effect of Artesunate
    He Rong-rong
    Zhou Huai-jun
    CHINESE JOURNAL OF INTEGRATIVE MEDICINE, 2008, 14 (04) : 312 - 316
  • [8] Research progress of nanovaccine in anti-tumor immunotherapy
    Yao, Min
    Liu, Xiyu
    Qian, Zhangbo
    Fan, Dianfa
    Sun, Xinjun
    Zhong, Liping
    Wu, Pan
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [9] Research Progress with Luteolin as an Anti-Tumor Agent
    Cai, Zhun
    Mao, Chenyang
    Wang, Yeqing
    Zhu, Zheyi
    Xu, Sisi
    Chen, Dongqing
    Chen, Yufeng
    Ruan, Wenjie
    Fang, Binbo
    NATURAL PRODUCT COMMUNICATIONS, 2022, 17 (11)
  • [10] Progress in Research on the Anti-tumor Effect of Artesunate
    何荣荣
    周怀君
    Chinese Journal of Integrative Medicine, 2008, (04) : 312 - 316